Skip to main content
Karen (Riedl) Reckamp, MD, Oncology, Los Angeles, CA

Karen Lynn (Riedl) Reckamp MD MS

Oncology•Los Angeles, CA

Thoracic Cancer

Director, Division of Medical Oncology Associate Director, Clinical Research, Cedars-Sinai Cancer

Join to view full profile

  • 8700 Beverly BlvdLos Angeles, CA 90048

  • Phone+1 310-423-7197

Dr. Reckamp is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Reckamp's full profileAlready have an account?

Summary

  • Dr. Karen Reckamp is an oncologist in Los Angeles, CA and is affiliated with Cedars-Sinai Medical Center. She received her medical degree from University of Chicago Pritzker School of Medicine and has been in practice over 15 years. She specializes in hematologic oncology and thoracic cancer and is experienced in lung cancer, thymic malignancies and mesothelioma.

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1998 - 2001
  • University of Chicago Division of the Biological Sciences The Pritzker School of Medicine
    University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1998

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2001 - 2028
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2013-2017
  • CMS Meaningful Use Stage 2 Certification Sunrise Ambulatory Care, Allscripts, 2013-2017
  • CMS Meaningful Use Stage 1 Certification Allscripts FollowMyHealth, Allscripts, 2013-2017

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Germline mutations and onset of lung adenocarcinoma in smokers and nonsmokers. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Brigatinib for Metastatic ALK Positive Non-Small Cell Lung Cancer. FDA Approvals and Their Incorporation into Clinical Practice 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018

Authored Content

  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020

Press Mentions

  • Kairos Pharma to Present Initial Phase 1 Data for ENV105 Lung Cancer Treatment at World Conference
    Kairos Pharma to Present Initial Phase 1 Data for ENV105 Lung Cancer Treatment at World ConferenceSeptember 3rd, 2025
  • Study Underlines Importance of COVID-19 Booster for Cancer Patients
    Study Underlines Importance of COVID-19 Booster for Cancer PatientsJuly 17th, 2025
  • Huntington Health Offers New, Less Invasive Lung Biopsy Procedure
    Huntington Health Offers New, Less Invasive Lung Biopsy ProcedureJune 25th, 2025

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Karen Reckamp, Dr. Karen Reckamp, MD, Dr. K Reckamp, Dr. Karen Lynn Reckamp